Section Arrow
Quote
NXTC.NASDAQ
- NextCure Inc
Quotes are at least 15-min delayed:2026/06/01 14:19 EDT
Regular Hours
Last
 3.7393
-2.4607 (-39.69%)
Day High 
6.96 
Prev. Close
6.2 
1-M High
11.14 
Volume 
263.37K 
Bid
3.67
Ask
3.74
Day Low
3.66 
Open
6.96 
1-M Low
5.845 
Market Cap 
22.39M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 8.15 
20-SMA 8.97 
50-SMA 10.03 
52-W High 15.7399 
52-W Low 0.45 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-16.82/-3.47
Enterprise Value
26.54M
Balance Sheet
Book Value Per Share
7.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.8531+0.4453+109.20%-- 
OTLKOutlook Therapeutics0.8626+0.1326+18.16%-- 
RXRXRecursion Pharmaceuticals3.7478+0.1578+4.40%-- 
GNTAGenenta Science SpA1.7301+0.7001+67.97%-- 
IBRXImmunityBio7.195-0.325-4.32%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.